...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Molecular medicine reports >Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use
【24h】

Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use

机译：Nifuroxazide对小鼠急性接枝移植物 - 与宿主病的治疗效果：老药，新用途

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Graft-vs.-host disease (GvHD) is a major and lethal complication of allogeneic bone marrow transplantation (allo-BMT). Although great development has been made, the treatment progress of this disorder is slow. Research has illustrated that STAT3 was critical for T cell alloactivation in GvHD. In the present study, the authors hypothesized that nifuroxazide, as the STAT3 inhibitor, treatment may attenuate the development of acute GvHD (aGvHD). The results demonstrated that nifuroxazide suppressed the development of aGvHD and significantly delayed aGvHD-induced lethality. Mice receiving nifuroxazide had mostly normal-appearing skin with minimal focal ulceration, mild edema and congestion in the liver, and a less-pronounced villus injury and less inflammatory infiltrate in the small intestine. Treatment with nifuroxazide inhibited the activation of STAT3, resulting in the regulation of the CD4(+) T cells and CD4(+) CD25(+) T cells and reduction of interferon-gamma and tumor necrosis factor-alpha levels. In conclusion, nifuroxazide may be efficacious for post-transplant of GvHD, providing a potent drug for use as a prophylactic or as a second-line therapy for aGvHD in clinical trials.
机译：移植物与宿主疾病（GVHD）是同种异体骨髓移植（Allo-BMT）的主要和致命并发症。虽然已经取得了巨大的发展，但这种疾病的治疗进展缓慢。研究表明，STAT3对于GVHD中的T细胞Alloactivation至关重要。在本研究中，作者假设硝砜，作为STAT3抑制剂，治疗可能会衰减急性GVHD（AGVHD）的发育。结果表明，Nifuroxazide抑制了AGVHD的发育，显着延迟了AGVHD诱导的致死率。接受硝基氧氮的小鼠主要出现正常出现的皮肤，肝脏溃疡，轻度水肿和肝脏中的充血，以及小肠中较少明显的绒毛损伤和较少的炎症性浸润。用硝苯胺肼处理抑制STAT3的活化，导致CD4（+）T细胞和CD4（+）CD25（+）T细胞的调节以及干扰素-γ和肿瘤坏死因子-α水平的降低。总之，镍酯氮杂物对于GVHD的移植后可能是有效的，提供一种用作预防性的药物或作为临床试验中AGVHD的第二线治疗。

著录项

  • 来源
    《Molecular medicine reports》 |2017年第3期|共7页
  • 作者

    Jia Huijie; Cui Jing; Jia Xiaolong; Zhao Jingjing; Feng Yuchen; Zhao Peijuan; Zang Dan; Yu Jian; Zhao Tiesuo; Wang Hui; Xu Kailin;

  • 作者单位

    Xinxiang Med Univ Dept Pathol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Dept Pathol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Henan Collaborat Innovat Ctr Mol Diag &

    Lab Med 601 Jinsui St Xinxiang 453000;

    Xinxiang Med Univ Dept Immunol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Dept Immunol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Henan Collaborat Innovat Ctr Mol Diag &

    Lab Med 601 Jinsui St Xinxiang 453000;

    Xinxiang Med Univ Affiliated Hosp 1 Dept Pathol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Affiliated Hosp 1 Dept Pathol Xinxiang 453000 Henan Peoples R China;

    Xinxiang Med Univ Henan Collaborat Innovat Ctr Mol Diag &

    Lab Med 601 Jinsui St Xinxiang 453000;

    Xinxiang Med Univ Henan Collaborat Innovat Ctr Mol Diag &

    Lab Med 601 Jinsui St Xinxiang 453000;

    Xuzhou Med Univ Lab Transplantat &

    Immunol 99 West Huaihai Rd Xuzhou 221002 Jiangsu Peoples R;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 基础医学;
  • 关键词

    nifuroxazide; signal transducer and activator of transcription 3; graft-vs.-host disease; immunotherapy;

    机译：硝苯胺胺;信号传感器和转录激活剂3;移植物与宿主疾病;免疫疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号